Literature DB >> 10535593

Infection after total knee arthroplasty. A retrospective study of the treatment of eighty-one infections.

H Segawa1, D T Tsukayama, R F Kyle, D A Becker, R B Gustilo.   

Abstract

BACKGROUND: The clinical presentation of an infection at the site of a total knee arthroplasty can be used as a guide to treatment, including the decision as to whether the prosthesis should be retained or removed. We reviewed the results of treatment of infection after total knee arthroplasty to evaluate the effectiveness of four treatment protocols based on the clinical setting of the infection.
METHODS: We retrospectively evaluated the results of treatment of eighty-one infections in seventy-six consecutive patients who either had an infection after a total knee arthroplasty or had multiple positive intraoperative cultures of specimens of periprosthetic tissue obtained during a revision total knee arthroplasty performed because of presumed aseptic loosening. The patients were managed according to one of four protocols. Five infections in five patients who had positive intraoperative cultures were treated with antibiotic therapy alone. Twenty-three early postoperative infections in twenty-one patients were treated with débridement, antibiotic therapy, and retention of the prosthesis. Twenty-nine late chronic infections in twenty-eight patients were treated with a delayed-exchange arthroplasty after a course of antibiotics. Seven acute hematogenous infections in six patients were treated with débridement, antibiotic therapy, and retention of the prosthesis. Seventeen infections in seventeen patients were not treated according to one of the four protocols. Sixteen late chronic infections were treated either with an arthrodesis (five infections) or with débridement, antibiotic therapy, and retention of the prosthesis (eleven infections). One acute hematogenous infection was treated with resection arthroplasty because of life-threatening sepsis.
RESULTS: The mean duration of follow-up was 4.0 years (range, 0.3 to 14.0 years). Eleven patients who had an arthrodesis, a resection arthroplasty, or an above-the-knee amputation after less than two years of follow-up were included in the study as individuals who had a failure of treatment. In the group of patients who were managed according to protocol, the initial course of treatment was successful for all five infections that were diagnosed on the basis of positive intraoperative cultures, five of the ten deep early infections, all thirteen superficial early infections, twenty-four of the twenty-nine late chronic infections, and five of the seven acute hematogenous infections. Only one of eleven prostheses in patients who had a late chronic infection that was not treated according to protocol was successfully retained after débridement.
CONCLUSIONS: Our treatment protocols, which were based on the clinical setting of the infection, were successful for most patients. A major factor associated with treatment failure was a compromised immune status. Bone loss and necrosis of the soft tissues around the joint also complicated the treatment of these infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10535593     DOI: 10.2106/00004623-199910000-00008

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  86 in total

Review 1.  [Antimicrobial prosthesis coatings].

Authors:  S Gravius; D C Wirtz
Journal:  Orthopade       Date:  2015-12       Impact factor: 1.087

2.  Comparison of infection control rates and clinical outcomes in culture-positive and culture-negative infected total-knee arthroplasty.

Authors:  Young-Hoo Kim; Sourabh S Kulkarni; Jang-Won Park; Jun-Shik Kim; Hyun-Keun Oh; Devarshi Rastogi
Journal:  J Orthop       Date:  2015-02-17

3.  Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination.

Authors:  Andrej Trampuz; Kerryl E Piper; Arlen D Hanssen; Douglas R Osmon; Franklin R Cockerill; James M Steckelberg; Robin Patel
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

4.  Assessing the gold standard: a review of 253 two-stage revisions for infected TKA.

Authors:  Tahir Mahmud; Matthew C Lyons; Douglas D Naudie; Steven J Macdonald; Richard W McCalden
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

5.  Failure of irrigation and débridement for early postoperative periprosthetic infection.

Authors:  Thomas K Fehring; Susan M Odum; Keith R Berend; William A Jiranek; Javad Parvizi; Kevin J Bozic; Craig J Della Valle; Terence J Gioe
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

6.  Prophylactic antibiotics do not affect cultures in the treatment of an infected TKA: a prospective trial.

Authors:  R Stephen J Burnett; Ajay Aggarwal; Stephanie A Givens; J Thomas McClure; Patrick M Morgan; Robert L Barrack
Journal:  Clin Orthop Relat Res       Date:  2009-08-11       Impact factor: 4.176

7.  Results after late polymicrobial, gram-negative, and methicillin-resistant infections in knee arthroplasty.

Authors:  José Cordero-Ampuero; Jaime Esteban; Eduardo García-Rey
Journal:  Clin Orthop Relat Res       Date:  2010-05       Impact factor: 4.176

8.  Two-stage treatment of infected total knee arthroplasty: two to thirteen year experience using an articulating preformed spacer.

Authors:  Claudio Carlo Castelli; Valerio Gotti; Roberto Ferrari
Journal:  Int Orthop       Date:  2014-01-26       Impact factor: 3.075

9.  Late infection of total knee arthroplasty inflamed by anti-TNFalpha, Infliximab therapy in rheumatoid arthritis.

Authors:  Takashi Yurube; Koichiro Takahi; Hajime Owaki; Takeshi Fuji; Masahiro Kurosaka; Minoru Doita
Journal:  Rheumatol Int       Date:  2009-05-16       Impact factor: 2.631

Review 10.  Functional outcomes of acutely infected knee arthroplasty: a comparison of different surgical treatment options.

Authors:  Ivan Dzaja; James Howard; Lyndsay Somerville; Brent Lanting
Journal:  Can J Surg       Date:  2015-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.